The shift from volume to value requires more than enthusiasm. It requires engineering discipline, business ownership and the ...

An update from Gain Therapeutics ( ($GANX) ) is now available. On December 18, 2025, Gain Therapeutics reported exploratory endpoint data from ...

ThoughtSpot is at the heart of new 'modern data stack' helping UK food brand Huel find answers more quickly than it used to with Business Intelligence ...

An analysis of ChatGPT use at work for a power user of AI. Includes top 10 uses cases and notes that ChatGPT is uses as a "reasoning engine" and not a search engine ...

Objective To determine whether a full-scale randomised control trial (RCT) assessing the efficacy and cost-effectiveness of a ...

Keypoint Intelligence has looked back at the main trends and key industry developments seen across print in 2025, while ...

Immunome (IMNM) surges after positive phase 3 results for varegacestat in desmoid tumors. Read the latest analysis on the ...

Neurosense Therapeutics Ltd. ( ($NRSN) ) has shared an announcement. On December 22, 2025, NeuroSense Therapeutics reported that a safety analysis ...

Most big Australian charities are using commercial profiling to ask for the right amount of money at the right time. But it’s ...

Liverpool Turn Attention to Rayan as Semenyo Chase CoolsLiverpool’s January planning is beginning to sharpen, shaped as much by availability as ambition. With the market narrowing and competition ...

Researchers have long believed — and the authors of a new study hypothesized — that schizophrenics have lower brain levels of the neurotransmitter serotonin, and that those lower levels are associated ...

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...